Evaluation of tumor markers CA-125 and CEA in acute myocardial infarction. 2006

Kenan Yalta, and Ahmet Yilmaz, and Okan Onur Turgut, and Taner Erselcan, and Mehmet Birhan Yilmaz, and Filiz Karadas, and Can Yontar, and Izzet Tandogan
Department of Cardiology, Cumhuriyet University, Sivas, Turkey.

Serum carbohydrate antigen (CA-125) and carcinoembryonic antigen (CEA) have always been of clinical importance in the diagnosis and follow-up of various tumors. This study was devised to investigate the relationship between these tumor markers and acute myocardial infarction (MI). Seventy consecutive cases (59 male patients with a diagnosis of acute ST segment elevation MI and 11 male patients with a diagnosis of non-ST segment elevation MI; mean age, 57+/-8.2 y) were admitted to the University Medical Center and were included in this study as "the patient group." All patients in the patient group underwent transthoracic echocardiographic examination on the third day of hospitalization. On the basis of echocardiographic findings, these 70 patients were grouped according to left ventricular ejection fraction (EF) values; EF <55% (group 1) (n=40) and EF >or=55% (group 2) (n=30). Other parameters, including systolic pulmonary artery pressure (sPAP) and mean pulmonary artery pressure (mPAP), were also measured on transthoracic echocardiography. Serial blood samples (for follow-up of myocardial enzymes (eg, creatine kinase MB [CKMB], troponin I [TnI], troponin T, and other routine parameters) were drawn from each patient. Serum concentrations of CEA and CA-125 measured at the 72nd hour of hospitalization and peak serum concentrations of CKMB and TnI in the patient group were collected for comparison between subgroups (groups 1 and 2) and with "the control group," which included 30 subjects (mean age, 54+/-7.6 y) with no history or evidence of overt cardiac disease and with normal echocardiographic findings. The presence of any condition characterized by potential elevations in CA-125, CEA, and myocardial enzymes (CKMB, TnI) was considered an exclusion criterion. Patients included in patient groups 1 and 2 differed significantly in terms of mean EF, mean sPAP, mean mPAP, and mean CA-125 values (P<.001 for CA-125; P<.05 for the other values). EF was found to be negatively correlated with sPAP (r=-0.692, P=.000) and mPAP (r=-0.393, P=.001). EF was also negatively correlated with CA-125 (r=-0.557, P=.000). A positive correlation was noted between CA-125 and sPAP (r=0.396, P=.001) and between CA-125 and mPAP (r=0.754, P=.000). A statistically significant difference was identified between the patient and control groups with regard to values for EF, PAP, CA-125, and myocardial enzymes (CKMB and TnI) (P<.05 for mPAP; P<.001 for the other values). The serum concentration of CA-125, but not of CEA, may be elevated in those with acute MI compared with normal subjects. Regardless of the presence of pulmonary hypertension, elevations in CA-125 during myocardial infarction were significantly correlated with the severity of left ventricular systolic dysfunction on transthoracic echocardiography.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009203 Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION). Cardiovascular Stroke,Heart Attack,Myocardial Infarct,Cardiovascular Strokes,Heart Attacks,Infarct, Myocardial,Infarction, Myocardial,Infarctions, Myocardial,Infarcts, Myocardial,Myocardial Infarctions,Myocardial Infarcts,Stroke, Cardiovascular,Strokes, Cardiovascular
D002272 Carcinoembryonic Antigen A glycoprotein that is secreted into the luminal surface of the epithelia in the gastrointestinal tract. It is found in the feces and pancreaticobiliary secretions and is used to monitor the response to colon cancer treatment. Antigens, CD66e,CD66e Antigen,Antigen, CD66e,Antigen, Carcinoembryonic,CD66e Antigens
D004452 Echocardiography Ultrasonic recording of the size, motion, and composition of the heart and surrounding tissues. The standard approach is transthoracic. Echocardiography, Contrast,Echocardiography, Cross-Sectional,Echocardiography, M-Mode,Echocardiography, Transthoracic,Echocardiography, Two-Dimensional,Transthoracic Echocardiography,2-D Echocardiography,2D Echocardiography,Contrast Echocardiography,Cross-Sectional Echocardiography,Echocardiography, 2-D,Echocardiography, 2D,M-Mode Echocardiography,Two-Dimensional Echocardiography,2 D Echocardiography,Cross Sectional Echocardiography,Echocardiography, 2 D,Echocardiography, Cross Sectional,Echocardiography, M Mode,Echocardiography, Two Dimensional,M Mode Echocardiography,Two Dimensional Echocardiography
D004562 Electrocardiography Recording of the moment-to-moment electromotive forces of the HEART as projected onto various sites on the body's surface, delineated as a scalar function of time. The recording is monitored by a tracing on slow moving chart paper or by observing it on a cardioscope, which is a CATHODE RAY TUBE DISPLAY. 12-Lead ECG,12-Lead EKG,12-Lead Electrocardiography,Cardiography,ECG,EKG,Electrocardiogram,Electrocardiograph,12 Lead ECG,12 Lead EKG,12 Lead Electrocardiography,12-Lead ECGs,12-Lead EKGs,12-Lead Electrocardiographies,Cardiographies,ECG, 12-Lead,EKG, 12-Lead,Electrocardiograms,Electrocardiographies, 12-Lead,Electrocardiographs,Electrocardiography, 12-Lead
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013318 Stroke Volume The amount of BLOOD pumped out of the HEART per beat, not to be confused with cardiac output (volume/time). It is calculated as the difference between the end-diastolic volume and the end-systolic volume. Ventricular Ejection Fraction,Ventricular End-Diastolic Volume,Ventricular End-Systolic Volume,Ejection Fraction, Ventricular,Ejection Fractions, Ventricular,End-Diastolic Volume, Ventricular,End-Diastolic Volumes, Ventricular,End-Systolic Volume, Ventricular,End-Systolic Volumes, Ventricular,Fraction, Ventricular Ejection,Fractions, Ventricular Ejection,Stroke Volumes,Ventricular Ejection Fractions,Ventricular End Diastolic Volume,Ventricular End Systolic Volume,Ventricular End-Diastolic Volumes,Ventricular End-Systolic Volumes,Volume, Stroke,Volume, Ventricular End-Diastolic,Volume, Ventricular End-Systolic,Volumes, Stroke,Volumes, Ventricular End-Diastolic,Volumes, Ventricular End-Systolic
D052279 Creatine Kinase, MB Form An isoenzyme of creatine kinase found in the CARDIAC MUSCLE. Isoenzyme CPK-MB,MB Creatine Kinase,Myocardial Creatine Kinase,CPK-MB, Isoenzyme,Creatine Kinase, MB,Creatine Kinase, Myocardial,Isoenzyme CPK MB,Kinase, MB Creatine,Kinase, Myocardial Creatine
D018394 CA-125 Antigen A carbohydrate antigen that occurs in tumors of the ovary as well as in breast, kidney, and gastrointestinal tract tumors and normal tissue. While it is tumor-associated, it is not tumor-specific and may have a protective function against particles and infectious agents at mucosal surfaces. Antigen CA-125,CA 125 Antigen,Mucin-16,Antigen CA 125,Antigen, CA 125,Antigen, CA-125,Mucin 16

Related Publications

Kenan Yalta, and Ahmet Yilmaz, and Okan Onur Turgut, and Taner Erselcan, and Mehmet Birhan Yilmaz, and Filiz Karadas, and Can Yontar, and Izzet Tandogan
August 1991, Geburtshilfe und Frauenheilkunde,
Kenan Yalta, and Ahmet Yilmaz, and Okan Onur Turgut, and Taner Erselcan, and Mehmet Birhan Yilmaz, and Filiz Karadas, and Can Yontar, and Izzet Tandogan
January 2001, Anticancer research,
Kenan Yalta, and Ahmet Yilmaz, and Okan Onur Turgut, and Taner Erselcan, and Mehmet Birhan Yilmaz, and Filiz Karadas, and Can Yontar, and Izzet Tandogan
October 2002, Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego,
Kenan Yalta, and Ahmet Yilmaz, and Okan Onur Turgut, and Taner Erselcan, and Mehmet Birhan Yilmaz, and Filiz Karadas, and Can Yontar, and Izzet Tandogan
November 2020, The journal of obstetrics and gynaecology research,
Kenan Yalta, and Ahmet Yilmaz, and Okan Onur Turgut, and Taner Erselcan, and Mehmet Birhan Yilmaz, and Filiz Karadas, and Can Yontar, and Izzet Tandogan
January 1986, Journal de gynecologie, obstetrique et biologie de la reproduction,
Kenan Yalta, and Ahmet Yilmaz, and Okan Onur Turgut, and Taner Erselcan, and Mehmet Birhan Yilmaz, and Filiz Karadas, and Can Yontar, and Izzet Tandogan
January 1988, European journal of gynaecological oncology,
Kenan Yalta, and Ahmet Yilmaz, and Okan Onur Turgut, and Taner Erselcan, and Mehmet Birhan Yilmaz, and Filiz Karadas, and Can Yontar, and Izzet Tandogan
May 1995, Gynecologic oncology,
Kenan Yalta, and Ahmet Yilmaz, and Okan Onur Turgut, and Taner Erselcan, and Mehmet Birhan Yilmaz, and Filiz Karadas, and Can Yontar, and Izzet Tandogan
December 1999, Disease markers,
Kenan Yalta, and Ahmet Yilmaz, and Okan Onur Turgut, and Taner Erselcan, and Mehmet Birhan Yilmaz, and Filiz Karadas, and Can Yontar, and Izzet Tandogan
June 2002, The Malaysian journal of pathology,
Kenan Yalta, and Ahmet Yilmaz, and Okan Onur Turgut, and Taner Erselcan, and Mehmet Birhan Yilmaz, and Filiz Karadas, and Can Yontar, and Izzet Tandogan
November 2022, World journal of gastrointestinal surgery,
Copied contents to your clipboard!